» Articles » PMID: 31609991

Effector Memory Differentiation Increases Detection of Replication-competent HIV-l in Resting CD4+ T Cells from Virally Suppressed Individuals

Abstract

Studies have demonstrated that intensive ART alone is not capable of eradicating HIV-1, as the virus rebounds within a few weeks upon treatment interruption. Viral rebound may be induced from several cellular subsets; however, the majority of proviral DNA has been found in antigen experienced resting CD4+ T cells. To achieve a cure for HIV-1, eradication strategies depend upon both understanding mechanisms that drive HIV-1 persistence as well as sensitive assays to measure the frequency of infected cells after therapeutic interventions. Assays such as the quantitative viral outgrowth assay (QVOA) measure HIV-1 persistence during ART by ex vivo activation of resting CD4+ T cells to induce latency reversal; however, recent studies have shown that only a fraction of replication-competent viruses are inducible by primary mitogen stimulation. Previous studies have shown a correlation between the acquisition of effector memory phenotype and HIV-1 latency reversal in quiescent CD4+ T cell subsets that harbor the reservoir. Here, we apply our mechanistic understanding that differentiation into effector memory CD4+ T cells more effectively promotes HIV-1 latency reversal to significantly improve proviral measurements in the QVOA, termed differentiation QVOA (dQVOA), which reveals a significantly higher frequency of the inducible HIV-1 replication-competent reservoir in resting CD4+ T cells.

Citing Articles

Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places.

Chen W, Berkhout B, Pasternak A Curr HIV/AIDS Rep. 2025; 22(1):15.

PMID: 39903363 PMC: 11794352. DOI: 10.1007/s11904-025-00723-6.


Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection.

Mu W, Patankar V, Kitchen S, Zhen A Viruses. 2024; 16(2).

PMID: 38399994 PMC: 10893210. DOI: 10.3390/v16020219.


Predictors of HIV rebound differ by timing of antiretroviral therapy initiation.

Li J, Melberg M, Kittilson A, Abdel-Mohsen M, Li Y, Aga E JCI Insight. 2024; 9(3).

PMID: 38329130 PMC: 10967395. DOI: 10.1172/jci.insight.173864.


A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV-infected cells.

Peterson J, Lewis C, Burgos S, Manickam A, Xu Y, Rowley A Cell Chem Biol. 2023; 30(12):1617-1633.e9.

PMID: 38134881 PMC: 10754471. DOI: 10.1016/j.chembiol.2023.11.009.


Estimating the contribution of CD4 T cell subset proliferation and differentiation to HIV persistence.

Reeves D, Bacchus-Souffan C, Fitch M, Abdel-Mohsen M, Hoh R, Ahn H Nat Commun. 2023; 14(1):6145.

PMID: 37783718 PMC: 10545742. DOI: 10.1038/s41467-023-41521-1.


References
1.
Chun T, Engel D, Berrey M, Shea T, Corey L, Fauci A . Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998; 95(15):8869-73. PMC: 21169. DOI: 10.1073/pnas.95.15.8869. View

2.
Mexas A, Graf E, Pace M, Yu J, Papasavvas E, Azzoni L . Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS. 2012; 26(18):2295-306. PMC: 4692807. DOI: 10.1097/QAD.0b013e32835a5c2f. View

3.
Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

4.
Kulpa D, Talla A, Brehm J, Pereira Ribeiro S, Yuan S, Bebin-Blackwell A . Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4 T Cells. J Virol. 2019; 93(24). PMC: 6880164. DOI: 10.1128/JVI.00969-19. View

5.
Geginat J, Sallusto F, Lanzavecchia A . Cytokine-driven proliferation and differentiation of human naive, central memory, and effector memory CD4(+) T cells. J Exp Med. 2001; 194(12):1711-9. PMC: 2193568. DOI: 10.1084/jem.194.12.1711. View